Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Published Date: 11 Sep 2024

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Routine breast cancer screening can bring better outcomes for patients

2.

Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.

3.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

4.

Testosterone recovery linked to overall survival in high-risk prostate cancer

5.

Skinny melanoma incidence is associated with vitamin D deficiency.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot